The difference between gynaecomastia and man boobs (pseudogynaecomastia) is clinically significant, yet the two conditions are frequently confused. Gynaecomastia involves the growth of actual glandular breast tissue in males, driven by hormonal imbalance, whilst pseudogynaecomastia — colloquially known as 'man boobs' or 'moobs' — results from excess fatty tissue depositing in the chest. Although both can look similar and cause distress, their causes, implications, and treatments differ considerably. Understanding which condition you have is the essential first step towards appropriate management and realistic expectations.

What Is Gynaecomastia and How Is It Diagnosed?

Gynaecomastia is the enlargement of glandular breast tissue in males, diagnosed clinically by a firm, rubbery disc beneath the nipple; blood tests, scrotal ultrasound, and imaging may be needed to identify underlying causes and exclude malignancy.

Gynaecomastia is the medical term for the enlargement of breast glandular tissue in males. Unlike simple weight gain, this condition involves the actual proliferation of ductal and stromal tissue within the breast — the same tissue that develops in females during puberty. Lobular development is typically absent in males, which helps distinguish true gynaecomastia from other breast changes. It is a relatively common condition; UK sources, including NICE CKS, note that pubertal gynaecomastia affects a significant proportion of adolescent boys (estimates vary, with some sources citing up to 70%), and it is also seen in a notable proportion of older men. Pubertal gynaecomastia is usually self-limiting.

Not sure if this is normal? Chat with one of our pharmacists →

The condition is typically identified by the presence of a firm, rubbery disc of tissue beneath the nipple-areola complex. This can affect one or both sides and may be accompanied by tenderness or sensitivity. A GP will usually diagnose gynaecomastia through a clinical examination, assessing the texture and location of the tissue. True glandular tissue feels distinctly different from soft fatty tissue.

A thorough assessment should always include a testicular examination, as testicular tumours can secrete hormones that drive gynaecomastia. To confirm the diagnosis and rule out underlying causes, a GP may request:

• Blood tests to assess hormone levels (oestradiol, testosterone, LH, FSH, prolactin), liver and kidney function, and thyroid hormones. Where a neoplasm is suspected, tumour markers including β-hCG and α-fetoprotein should also be measured

• Scrotal ultrasound if a testicular tumour is clinically suspected

• Breast ultrasound if there is diagnostic uncertainty about the nature of the breast tissue

• Mammography where malignancy is suspected, particularly in the presence of a unilateral, hard, or irregular mass — usage varies by breast clinic protocol and clinical suspicion

It is worth noting that male breast cancer, whilst rare, accounts for less than 1% of all breast cancers in the UK. Any rapidly growing, hard, or asymmetrical lump should be assessed promptly. In line with NICE NG12 (Suspected Cancer: Recognition and Referral), clinicians should consider an urgent two-week-wait referral for men aged 50 or over with a unilateral, firm subareolar mass with or without nipple changes or discharge. An urgent referral should also be considered at any age if clinical features are strongly suspicious of malignancy.

Pseudogynaecomastia: When Excess Fat Affects the Chest

Pseudogynaecomastia is the accumulation of soft adipose tissue in the chest due to excess body fat, not a hormonal disorder, and typically feels diffuse and compressible rather than firm.

Pseudogynaecomastia is a distinctly different condition from true gynaecomastia. Rather than involving glandular breast tissue, it is caused by an accumulation of adipose (fatty) tissue in the chest area. It is not a hormonal or glandular disorder but a consequence of excess body fat, which can deposit in the chest region just as it does elsewhere in the body. It is sometimes referred to informally as 'man boobs' or 'moobs', though neutral clinical terminology is preferred.

This condition is increasingly prevalent in the UK, where rates of overweight and obesity continue to rise. According to NHS Digital's Statistics on Obesity, Physical Activity and Diet (England), approximately 64% of adults in England are overweight or living with obesity, making pseudogynaecomastia a common concern. The chest fat tends to feel soft and diffuse, without the firm, centralised disc of tissue that characterises true gynaecomastia.

Pseudogynaecomastia does not carry the same hormonal implications as true gynaecomastia, and in most cases it does not require medical investigation beyond a standard clinical assessment. However, it can have a significant psychological impact, affecting self-esteem and social confidence in some men. Acknowledging this psychological dimension is an important part of holistic care.

Whilst pseudogynaecomastia is not a medical emergency, it can sometimes coexist with true gynaecomastia, making professional assessment valuable for anyone uncertain about the nature of their chest enlargement.

Key Differences Between Gynaecomastia and Chest Fat

Gynaecomastia feels firm and is concentrated beneath the nipple, is often tender, and is hormonally driven; pseudogynaecomastia feels soft and diffuse, is not tender, and responds to weight loss.

Understanding the distinction between gynaecomastia and pseudogynaecomastia is essential, both for appropriate management and for setting realistic expectations about treatment. The two conditions may look similar on the surface but differ considerably in their underlying biology, feel, and clinical significance.

Key differences at a glance:

• Tissue type: Gynaecomastia involves firm glandular breast tissue; pseudogynaecomastia involves soft adipose tissue

• Location: Glandular tissue in gynaecomastia is typically concentrated beneath and around the nipple; chest fat in pseudogynaecomastia is more diffusely distributed

• Feel on palpation: Gynaecomastia feels firm or rubbery; pseudogynaecomastia feels soft and compressible

• Tenderness: Gynaecomastia is often associated with nipple or breast tenderness, particularly in active phases; pseudogynaecomastia is generally not tender

• Response to weight loss: Pseudogynaecomastia typically reduces with overall weight loss; long-standing (greater than 12 months) fibrotic gynaecomastia is unlikely to regress with diet and exercise alone. However, recent-onset or obesity-related gynaecomastia may improve once the underlying trigger is addressed

• Hormonal involvement: Gynaecomastia is linked to an imbalance between oestrogen and androgen activity; pseudogynaecomastia is not

A simple self-assessment technique involves lying flat and gently pressing the fingers towards the nipple from either side. If a firm, disc-like structure is felt beneath the nipple, glandular tissue is likely present. If the tissue remains uniformly soft throughout, it is more consistent with fatty deposition. However, this is not a substitute for professional clinical evaluation. Anyone who notices a hard, irregular, or rapidly growing lump, nipple discharge (particularly bloody or serous), skin or nipple changes, or unilateral breast enlargement should seek prompt medical assessment rather than relying on self-examination alone.

Causes and Risk Factors for Each Condition

Gynaecomastia is caused by oestrogen–androgen imbalance from medications, health conditions, or physiological changes; pseudogynaecomastia is caused by excess body fat, though obesity can trigger both conditions simultaneously.

The causes of gynaecomastia and pseudogynaecomastia are quite different, though both can be influenced by lifestyle and health factors.

Gynaecomastia arises from a relative imbalance between oestrogen and androgen (testosterone) activity in breast tissue. Common causes include:

• Physiological changes: Neonatal gynaecomastia (due to maternal oestrogens), pubertal gynaecomastia (transient hormonal fluctuations), and age-related gynaecomastia in older men (declining testosterone levels)

• Medications: A significant number of drugs are associated with gynaecomastia. Examples include spironolactone, cimetidine, digoxin, anti-androgens such as bicalutamide, 5-alpha-reductase inhibitors such as finasteride and dutasteride, some antipsychotics, anabolic steroids, and certain antiretrovirals such as efavirenz. Prescribing information for individual medicines is available via the BNF and the relevant Summary of Product Characteristics (SmPC) on the electronic Medicines Compendium (eMC). The MHRA has issued specific Drug Safety Updates for some of these agents — for example, in relation to finasteride and breast changes. If you think a medicine may be causing gynaecomastia, do not stop or change it without first speaking to your prescriber

• Underlying health conditions: Hypogonadism (including Klinefelter syndrome, which also carries an elevated risk of male breast cancer), hyperthyroidism, liver cirrhosis, chronic kidney disease, and oestrogen- or hCG-secreting tumours

• Recreational substances: Anabolic steroids used in bodybuilding and alcohol (primarily via liver disease and altered hormone metabolism) are recognised risk factors. Cannabis has been reported in association with gynaecomastia in some cases, though the evidence is inconsistent and causality has not been established

Pseudogynaecomastia, by contrast, is primarily driven by:

• Excess caloric intake and sedentary behaviour, leading to generalised adiposity

• Obesity, which itself can elevate oestrogen levels through peripheral aromatisation of androgens in fat tissue — this can sometimes trigger or worsen true gynaecomastia simultaneously

• Genetic predisposition to fat distribution in the chest region

Obesity-related hormonal changes can blur the boundary between the two conditions, as elevated body fat can promote both fatty deposition and glandular stimulation. This overlap underscores the importance of professional assessment rather than self-diagnosis.

Patient safety note: If you suspect that a prescribed medicine is causing breast changes, please report this via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Do not stop or switch any prescribed medicine without first seeking medical advice.

When to See a GP and What to Expect on the NHS

See a GP promptly for any hard, irregular, or rapidly growing lump, nipple discharge, skin changes, or unilateral breast enlargement; NICE NG12 recommends an urgent two-week-wait referral for suspected male breast cancer.

Many men feel embarrassed to seek help for chest enlargement, but both gynaecomastia and pseudogynaecomastia are legitimate medical concerns that GPs are well-equipped to assess. Early consultation is particularly important if the enlargement is new, rapidly progressing, painful, or affecting only one side.

Contact your GP promptly if you notice:

• A hard, irregular, or rapidly growing lump in the chest or under the nipple

• Nipple discharge, particularly if bloody or serous (any nipple discharge in men is abnormal and warrants assessment)

• Skin changes, nipple retraction, or ulceration over the breast area

• Unilateral (one-sided) breast enlargement without an obvious cause

• Breast changes accompanied by other symptoms such as fatigue, unexplained weight loss, or testicular changes

In line with NICE NG12, clinicians should consider an urgent two-week-wait referral for suspected male breast cancer in men aged 50 or over with a unilateral, firm subareolar mass with or without nipple changes or discharge, and at any age where clinical features are strongly suspicious.

During a GP appointment, you can expect a thorough history — including a review of all medications, recreational substance use, and any relevant medical conditions — followed by a physical examination that includes assessment of the testes. If gynaecomastia is suspected, blood tests and possibly imaging will be arranged. The GP may also refer you to an endocrinologist or breast surgeon depending on findings.

For pseudogynaecomastia, the NHS approach typically centres on lifestyle modification, with referral to dietetic services or weight management programmes where appropriate. NHS Tier 2 and Tier 3 weight management services may be accessible depending on your local integrated care board (ICB). Cosmetic surgery for either condition is not routinely funded on the NHS; eligibility varies by ICB and may require an Individual Funding Request (IFR) based on clinical and psychological criteria.

Treatment Options Available in the UK

True gynaecomastia is managed by addressing the underlying cause, watchful waiting, specialist-initiated off-label SERMs, or surgery; pseudogynaecomastia is primarily treated with sustained weight loss, exercise, and, where appropriate, private liposuction.

Treatment for gynaecomastia and pseudogynaecomastia differs considerably, reflecting their distinct underlying causes.

For true gynaecomastia, management depends on the underlying cause and duration:

• Addressing the cause: If a medication is responsible, a specialist or GP may consider switching to an alternative under medical supervision, which may lead to gradual resolution. Treating an underlying condition such as hyperthyroidism or hypogonadism can also help. Do not stop or change any prescribed medicine without medical advice

• Watchful waiting: Pubertal gynaecomastia often resolves spontaneously within one to two years and may not require active treatment, as outlined in NICE CKS guidance on gynaecomastia

• Medical therapy: In selected cases — particularly where gynaecomastia is recent in onset (ideally within six to twelve months), tender, and causing significant distress — a specialist may consider off-label use of a selective oestrogen receptor modulator (SERM) such as tamoxifen or raloxifene. These medicines are not licensed specifically for gynaecomastia in the UK (see BNF and individual SmPCs for prescribing information and safety considerations), and the evidence base is limited. They should only be initiated by a specialist following a careful discussion of potential benefits and risks. Aromatase inhibitors such as anastrozole have limited evidence of efficacy in typical gynaecomastia and are not routinely recommended

• Surgery: Surgical correction (subcutaneous mastectomy or liposuction-assisted gland excision) is the most definitive treatment for established gynaecomastia. This is available privately across the UK; NHS funding is not routine and varies by ICB. Patients considering surgery should seek information from accredited surgeons and refer to guidance from bodies such as the Royal College of Surgeons (RCS) or the British Association of Aesthetic Plastic Surgeons (BAAPS)

For pseudogynaecomastia, the primary treatment is:

• Sustained weight loss through a calorie-controlled diet and regular physical activity, which reduces overall body fat including chest fat

• Structured exercise, particularly resistance training, which can improve chest muscle definition and reduce the visual prominence of fatty tissue

• Surgical liposuction, available privately, for those who have achieved a stable weight but retain localised chest fat

Regardless of the condition, psychological support should not be overlooked. Talking therapies such as cognitive behavioural therapy (CBT) are available through NHS Talking Therapies for Anxiety and Depression services, which offer self-referral in many areas. These can be beneficial for men experiencing body image concerns or reduced self-esteem related to chest appearance.

Frequently Asked Questions